Skip to main content

Table 2 Spearman’s correlations of CETP activity and PCSK9 levels with clinical and metabolic variables

From: Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

 

CETP

PCSK9

 

r

P

r

P

CETP

1.000

0.256a

<0.0001

PCSK9

0.256a

<0.0001

1.000

Age

−0.088

0.063

0.045

0.346

BMI

0.020

0.679

0.052

0.268

SBP

0.208

<0.0001

0.123

0.022

DBP

0.129

0.016

0.085

0.112

Cholesterol

0.585

<0.0001

0.194

<0.0001

Triglycerides

0.491

<0.0001

0.210

<0.0001

LDL-C

0.412

<0.0001

0.179

<0.0001

HDL-C

0.134

0.004

0.109

0.021

ApoB100

0.494

<0.0001

0.194

<0.0001

ApoA1

−0.002

0.970

0.135

0.004

Glucose

0.186

<0.0001

0.215

<0.0001

LCAT

−0.251

<0.0001

−0.072

0.127

Lp particles number

 Total VLDL

0.419

<0.0001

0.176

<0.0001

 Large VLDL

0.411

<0.0001

0.160

0.001

 Medium VLDL

0.413

<0.0001

0.172

<0.0001

 Small VLDL

0.420

<0.000

0.177

<0.0001

 Total LDL

0.300

<0.0001

0.134

0.004

 Large LDL

0.246

<0.0001

0.093

0.049

 Medium LDL

0.234

<0.0001

0.111

0.019

 Small LDL

0.332

<0.0001

0.152

0.001

 Total HDL

0.098

0.038

0.024

0.614

 Large HDL

0.109

0.021

0.043

0.359

 Medium HDL

−0.193

<0.0001

−0.044

0.356

 Small HDL

0.241

<0.0001

0.071

0.136

Lp size

 VLDL

−0.276

<0.0001

−0.114

0.015

 LDL

−0.200

<0.0001

−0.107

0.023

 HDL

−0.362

<0.0001

−0.104

0.027

  1. aAfter adjusting PCSK9 for age, gender, BMI, SBP, LDL-C, triglycerides and glucose, the Spearman’s correlation with CETP remained significant (r = 0.158, P = 0.003)
  2. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C LDL cholesterol, HDL-C HDL cholesterol